Le Lézard
Classified in: Health
Subject: SVY

US Blood Banking Market Future Horizons and Growth Strategies 2021: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities


NEW YORK, Nov. 17, 2017 /PRNewswire/ --

Complete report $9,700.  DataPack (test volumes, sales forecasts, supplier shares) $6,300.

Read the full report: https://www.reportlinker.com/p05121992

LeadingMarketResearch.com's new strategic analysis is prepared in order to help current suppliers and potential market entrants identify and evaluate emerging opportunities and assist industry executives in developing effective business, new product development and marketing strategies. 
 
Rationale

During the next five years, the US blood banking market is expected to undergo significant transformation, which will result from the convergence of several trends, including more stringent regulations; advances in diagnostic technologies, IT, system engineering and automation; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and differentiation are more critical than underlying technology. 

The changes in the marketplace will create exciting opportunities for new instruments and reagent systems, as well as auxiliary products, such as specimen preparation devices, controls, calibrators, and innovative IT applications.

Strategic Recommendations

- New product development opportunities with significant market appeal.
- Alternative market penetration strategies.
- Potential market entry barriers and risks.

The report explores future marketing and technological trends in the US; provides estimates of the test volume, instrument placements and sales; compares features of major automated and semi-automated analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next ten years.

Blood Typing and Grouping Tests

ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin,
Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s),
Antiglobulin (Direct, C3 + IgG, IgG,  C3),
Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du).

Infectious Disease Screening Tests

AIDS (HIV NAT, HIV-1/2), Cytomegalovirus,
Hepatitis (HAV NAT, HBV NAT, HBs Ag,  
Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT,
Syphilis, West Nile Virus NAT.

Sales and Market Share Analysis

Sales and market share estimates of leading
suppliers of blood banking of reagents
and instruments, by individual product.

Competitive Assessments

Strategic assessments of major suppliers and
emerging market entrants, including their sales,
product portfolios, marketing tactics, and new
products in RandD.

Market Segmentation Analysis

- Comprehensive market segmentation
analysis, including review of the market
dynamics, trends, structure, size, growth,
and key suppliers.

- Test volume and sales forecasts for over 40
blood banking tests, including NAT, by market segment:

- Blood Centers
- Plasma Fractionation Facilities
- Hospitals
- Commercial/Private Laboratories
- Military Blood Banks

Current and Emerging Products

- Analysis of current and emerging blood banking tests.

- Review of automated and semi-automated
analyzers, including their operating
characteristics, features, and selling prices.

Technology Review

- Assessment of current and emerging technologies,
and their potential applications for the blood banking market.

- Comprehensive lists of companies developing
or marketing new technologies and products by test.

Contains 460 pages and 53 tables


Read the full report: https://www.reportlinker.com/p05121992

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker


These press releases may also interest you

at 08:07
Lindus Health, the "anti-CRO" running radically faster, more reliable clinical trials for life science pioneers, has released a comprehensive contract research organization (CRO) offering tailor-made for sponsors looking to bring diagnostic products...

at 08:05
Koneksa, a healthcare technology company pioneering evidence-based digital biomarkers, announced today the enrollment of the first patient in a pilot study collecting patient-generated health data (PGHD) during proton radiotherapy for lung cancer in...

at 08:05
Roivant and Kinevant Sciences, a clinical-stage biopharmaceutical company developing new medicines for rare inflammatory and autoimmune diseases, today announced the successful completion of enrollment in its Phase 2 study evaluating namilumab for...

at 08:05
Revvity, Inc. will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024 at 8:40 a.m. PT in Las Vegas, NV. Senior Vice President and Chief Financial Officer Max Krakowiak will provide an update on the Company and its...

at 08:05
Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation neuropsychiatric therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has notified the...

at 08:05
Microbion Corporation today announced that the company won the Advanced Wound Care Summit's Innovation Showcase award. The Innovation Showcase was designed to give presenters, who were picked by a selection committee, an opportunity to demonstrate...



News published on and distributed by: